• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    11/14/25 6:04:07 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Lexeo Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    52886X107

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    Balyasny Asset Management L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,394,721.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,394,721.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,394,721.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    BAM GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,394,721.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,394,721.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,394,721.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    Balyasny Asset Management Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,394,721.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,394,721.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,394,721.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    Dames GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,394,721.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,394,721.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,394,721.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    52886X107


    1Names of Reporting Persons

    Dmitry Balyasny
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,394,721.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,394,721.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,394,721.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Lexeo Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    345 Park Avenue South, Floor 6, New York, NY, 10010, UNITED STATES
    Item 2. 
    (a)Name of person filing:

    This statement is being filed by (1) Balyasny Asset Management L.P., a Delaware limited partnership ("BAM"), (2) BAM GP LLC, a Delaware limited liability company ("BAM GP"), (3) Balyasny Asset Management Holdings LP, a Delaware limited partnership ("BAM Holdings"), (4) Dames GP LLC, a Delaware limited liability company ("Dames"), and (5) Dmitry Balyasny, a United States citizen (collectively, the "Reporting Persons"). BAM GP is the General Partner of BAM. BAM Holdings is the Sole Member of BAM GP. Dames is the General Partner of BAM Holdings. Dmitry Balyasny is the Managing Member of Dames.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of BAM, BAM GP, BAM Holdings, Dames, and Mr. Balyasny is located at 444 West Lake Street, 50th Floor, Chicago, IL 60606.
    (c)Citizenship:

    (1) BAM is a Delaware limited partnership, (2) BAM GP is a Delaware limited liability company, (3) BAM Holdings is a Delaware limited partnership, (4) Dames is a Delaware limited liability company, and (5) Mr. Balyasny is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    52886X107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    By virtue of its position as the investment manager of Atlas Diversified Master Fund, Ltd. ("ADMF"), the direct holder of the 5,394,721 shares (including 1,480,933 shares of Common Stock issuable upon exercise of Warrants) of common stock, par value $0.0001 per share ("Shares"), reported herein, BAM may be deemed to exercise voting and investment power over such Shares held by ADMF and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM, BAM GP may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares. By virtue of its position as the Sole Member of BAM GP, BAM Holdings may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM Holdings, Dames may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares. By virtue of his position as the Managing Member of Dames, Mr. Balyasny may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares.
    (b)Percent of class:

    The report amount consists of 3,913,788 Shares and 1,480,933 Shares issuable upon the exercise of 1,480,933 Warrants subject to the Beneficial Ownership Limitation (as defined herein). The Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 9.99% of the Shares outstanding as a result of the exercise (the "Beneficial Ownership Limitation").
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Each of the Reporting Persons has the sole power to dispose or to direct the disposition of 5,394,721 Shares (including 1,480,933 shares of Common Stock issuable upon exercise of Warrants).

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    Each of the Reporting Persons has the sole power to dispose or to direct the disposition of 5,394,721 Shares (including 1,480,933 shares of Common Stock issuable upon exercise of Warrants).

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    ADMF, a Cayman Islands exempted company that is an investment management client of BAM, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Balyasny Asset Management L.P.
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:11/10/2025
     
    BAM GP LLC
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:11/10/2025
     
    Balyasny Asset Management Holdings LP
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:11/10/2025
     
    Dames GP LLC
     
    Signature:/s/ Scott Schroeder
    Name/Title:Scott Schroeder / Authorized Signatory
    Date:11/10/2025
     
    Dmitry Balyasny
     
    Signature:/s/ Dmitry Balyasny
    Name/Title:Dmitry Balyasny / Self
    Date:11/10/2025
    Get the next $LXEO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    11/20/2025$19.00Overweight
    Cantor Fitzgerald
    10/15/2025$30.00Buy
    Guggenheim
    7/31/2025$20.00Outperform
    Oppenheimer
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    More analyst ratings

    $LXEO
    SEC Filings

    View All

    SEC Form EFFECT filed by Lexeo Therapeutics Inc.

    EFFECT - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    11/28/25 12:15:23 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Lexeo Therapeutics Inc.

    424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    11/26/25 4:29:12 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/20/25 4:30:17 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

    FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures of Friedreich ataxia, including left ventricular mass index and the modified Friedreich Ataxia Rating Scale Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participa

    11/5/25 7:36:55 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

    NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO) ("Lexeo"), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commission and other expenses payable by Lexeo in connection with the transaction and including the full exercise of the underwriters' option to purchase additional shares. In the public offering, Lexeo sold 17,968,750 shares of its common stock at $8.00 per sh

    10/20/25 4:05:00 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

    NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten public offering and concurrent private placement for gross proceeds to Lexeo of approximately $135 million, before deducting underwriting discounts and commissions and other expenses payable by Lexeo in connection with the transactions and excluding any exercise of the underwriters' option to purchase additional shares. All of the shares and pre-funded warrants are to be sold by Lexeo. Lexeo offered 15,625,000 shares of its common stock in the p

    10/16/25 11:29:54 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Townsend Richard Nolan sold $10,447 worth of shares (1,127 units at $9.27), decreasing direct ownership by 0.47% to 240,991 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/20/25 5:21:29 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Adler Eric sold $5,701 worth of shares (615 units at $9.27), decreasing direct ownership by 0.84% to 72,646 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/20/25 5:20:13 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Development Officer See Tai Sandi sold $3,578 worth of shares (386 units at $9.27), decreasing direct ownership by 0.59% to 65,476 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/20/25 5:19:10 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/26/24 5:00:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Lexeo Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $19.00

    11/20/25 8:07:20 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Lexeo Therapeutics with a new price target

    Guggenheim initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $30.00

    10/15/25 8:29:39 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Lexeo Therapeutics with a new price target

    Oppenheimer initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $20.00

    7/31/25 7:37:07 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Leadership Updates

    Live Leadership Updates

    View All

    Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

    12/19/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

    Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

    11/13/24 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

    Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

    8/12/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Financials

    Live finance-specific insights

    View All

    Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

    Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

    10/30/24 6:14:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

    NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

    7/11/24 8:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LXEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 5:49:30 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 4:45:58 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 12:32:15 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care